Curegenetics
2 known investors
Cure Genetics develops two biotechnology platforms: AIMS CAR-NKT, a cell therapy targeting solid tumors such as clear cell renal carcinoma, and the VELP directed-evolution library platform for gene therapy applications addressing the nervous system, heart, and kidneys. Its VELP platform has licensing collaborations with pharmaceutical companies including Boehringer Ingelheim.
BiotechHealthtech
Investors · 2
Frequently asked questions
- What does Curegenetics do?
- Cure Genetics develops two biotechnology platforms: AIMS CAR-NKT, a cell therapy targeting solid tumors such as clear cell renal carcinoma, and the VELP directed-evolution library platform for gene therapy applications addressing the nervous system, heart, and kidneys. Its VELP platform has licensing collaborations with pharmaceutical companies including Boehringer Ingelheim.
- Who are Curegenetics's investors?
- Curegenetics's investors include Blue Ocean Capital Group, Qiming Venture Partners.